DDInter806 DDInter1840
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Ganciclovir {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Pentamidine {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Pentamidine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Ganciclovir {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Pentamidine {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Ganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Ganciclovir {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) covaries with {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Ganciclovir (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Ganciclovir (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Trabectedin (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Ganciclovir (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) covaries with CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)